KR20190073576A - 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 - Google Patents

혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 Download PDF

Info

Publication number
KR20190073576A
KR20190073576A KR1020197016644A KR20197016644A KR20190073576A KR 20190073576 A KR20190073576 A KR 20190073576A KR 1020197016644 A KR1020197016644 A KR 1020197016644A KR 20197016644 A KR20197016644 A KR 20197016644A KR 20190073576 A KR20190073576 A KR 20190073576A
Authority
KR
South Korea
Prior art keywords
fviii
recombinant polypeptide
leu
cys
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197016644A
Other languages
English (en)
Korean (ko)
Inventor
사빈 페스텔
엘마르 라쿠엣
토마스 바이머
Original Assignee
체에스엘 베링 렝나우 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 렝나우 아게 filed Critical 체에스엘 베링 렝나우 아게
Publication of KR20190073576A publication Critical patent/KR20190073576A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197016644A 2016-11-11 2017-11-10 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 Withdrawn KR20190073576A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16198497 2016-11-11
EP16198497.6 2016-11-11
PCT/EP2017/078840 WO2018087271A1 (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Publications (1)

Publication Number Publication Date
KR20190073576A true KR20190073576A (ko) 2019-06-26

Family

ID=57389201

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016644A Withdrawn KR20190073576A (ko) 2016-11-11 2017-11-10 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드

Country Status (12)

Country Link
US (1) US11890327B2 (enExample)
EP (1) EP3538134B1 (enExample)
JP (1) JP2020504082A (enExample)
KR (1) KR20190073576A (enExample)
CN (1) CN110381986B (enExample)
AU (1) AU2017358865A1 (enExample)
CA (1) CA3043397A1 (enExample)
DK (1) DK3538134T3 (enExample)
ES (1) ES2908008T3 (enExample)
SG (2) SG10201912768YA (enExample)
TW (1) TW201828974A (enExample)
WO (1) WO2018087271A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022234963A1 (ko) * 2021-05-04 2022-11-10 (주)케어젠 혈액 응고 활성을 갖는 펩타이드와 이의 용도

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
DE69735421T2 (de) 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第viii因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
CA2484155C (en) 2002-04-29 2015-10-13 Baxter International Inc. Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
KR20070092754A (ko) 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
NZ572050A (en) 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
JP2010529155A (ja) 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのvwf安定化fviii製剤及びfviiiなしのvwf製剤の使用
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
CN104411323A (zh) * 2012-04-24 2015-03-11 诺和诺德A/S(股份有限公司) 适用于治疗血友病的药物组合物
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
EP3008084A2 (en) 2013-06-12 2016-04-20 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
JP6605593B2 (ja) 2014-06-06 2019-11-13 オクタファルマ・アーゲー 第viii因子およびフォン・ヴィルブランド因子ペプチドを含む製剤
AU2015283822B2 (en) 2014-07-02 2019-10-03 CSL Behring Lengnau AG Modified von willebrand factor
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022234963A1 (ko) * 2021-05-04 2022-11-10 (주)케어젠 혈액 응고 활성을 갖는 펩타이드와 이의 용도
CN117255796A (zh) * 2021-05-04 2023-12-19 凯尔格恩有限公司 具有凝血活性的肽及其用途

Also Published As

Publication number Publication date
SG11201903954WA (en) 2019-05-30
ES2908008T3 (es) 2022-04-27
EP3538134A1 (en) 2019-09-18
EP3538134B1 (en) 2021-12-29
US20210268071A1 (en) 2021-09-02
AU2017358865A1 (en) 2019-05-09
SG10201912768YA (en) 2020-02-27
JP2020504082A (ja) 2020-02-06
TW201828974A (zh) 2018-08-16
CN110381986A (zh) 2019-10-25
WO2018087271A1 (en) 2018-05-17
CA3043397A1 (en) 2018-05-17
DK3538134T3 (da) 2022-02-07
US11890327B2 (en) 2024-02-06
CN110381986B (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
US10688157B2 (en) Truncated von Willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
KR20180094114A (ko) 돌연변이된 절단된 폰 빌레브란트 인자
AU2017358861B2 (en) Truncated von Willebrand Factor polypeptides for treating hemophilia
KR20180012303A (ko) 변형된 폰 빌레브란트 인자의 제조 방법
KR20200018690A (ko) 절단된 vwf에 의한 fviii 면역원성의 조절
US20220348637A1 (en) Polypeptides for inducing tolerance to factor viii
HK40013462B (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
HK1250625B (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359A (en) Truncated von willebrand factor polypeptides for treating hemophilia
HK40008359B (en) Truncated von willebrand factor polypeptides for treating hemophilia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190610

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201109

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210215

WITB Written withdrawal of application